Bone Biologics
BBLG
6 hedge funds and large institutions have $55.8K invested in Bone Biologics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.05% less ownership
Funds ownership: 3.5% → 2.45% (-1.1%)
14% less funds holding
Funds holding: 7 → 6 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
70% less capital invested
Capital invested by funds: $183K → $55.8K (-$128K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$21K |
| 2 |
Citigroup
New York
|
+$6.79K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$60.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.1K |
| 3 |
HF
HRT Financial
New York
|
-$10.4K |
| 4 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
-$1K |
| 5 |
MWA
MFA Wealth Advisors
Pittsburgh,
Pennsylvania
|
-$858 |
BBLG Hedge Fund Activity: Q4 2024 in Review
6 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q4 2024, worth a combined $55.8K — down 70% from $183K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BBLG and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $21K. The largest seller was Morgan Stanley, exiting entirely with an estimated $60.8K sold.
- 6 institutional investors held Bone Biologics (BBLG) as of Q4 2024, down from 7 in Q3 2024.
- Funds reported $55.8K of Bone Biologics stock for Q4 2024, down 70% quarter-over-quarter.
- 2 funds opened new Bone Biologics positions in Q4 2024 and 3 closed out, a net change of -1 holder.
- The largest Bone Biologics buyer in Q4 2024 was Geode Capital Management, an estimated $21K added.
- The largest Bone Biologics seller in Q4 2024 was Morgan Stanley, an estimated $60.8K sold.
Based on aggregated 13F filings for Q4 2024.